What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Portfolio Pulse from Vandana Singh
Aethlon Medical Inc (NASDAQ:AEMD) announced positive results from an in vitro study of its Hemopurifier in removing extracellular vesicles from plasma, a key step ahead of its planned phase 1 oncology trials in Australia and India. The Hemopurifier aims to treat patients with solid tumors under anti-PD-1 monotherapy, including treatments like Merck & Co Inc's (NYSE:MRK) Keytruda and Bristol-Myers Squibb Co's (NYSE:BMY) Opdivo. AEMD shares rose 6.11% following the announcement.
May 10, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical announced positive results from a study of its Hemopurifier, leading to a 6.11% increase in its stock price. The company is preparing for phase 1 oncology trials in Australia and India.
The positive study results directly impact AEMD's stock by increasing investor confidence in its Hemopurifier technology and its potential in upcoming clinical trials.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Bristol-Myers Squibb's Opdivo is referenced in the context of Aethlon's Hemopurifier study for treating solid tumors, which could influence BMY's standing in cancer therapy.
The mention of BMY's Opdivo alongside AEMD's Hemopurifier study suggests a potential collaboration or comparison, indirectly affecting BMY's image but not its immediate stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Merck's Keytruda is mentioned as a treatment in conjunction with Aethlon's Hemopurifier for patients with solid tumors, potentially impacting MRK's relevance in oncology treatments.
While the news is positive for AEMD, it indirectly mentions MRK's Keytruda, potentially affecting its market position but not directly impacting its stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50